View Older Stories View More Recent Stories

Jul 12, 2021 06:45AM Interim Results from Phase 2/3 Studies of Molnupiravir, an Investigational Oral Antiviral Therapeutic for Mild to Moderate COVID-19, Presented at the European Congress of Clinical Microbiology & I
Jul 6, 2021 06:47AM FDA Announces Expanded Indication for Merck's (MRK) KEYTRUDA® in Locally Advanced Cutaneous Squamous Cell Carcinoma (cSCC)
Jul 6, 2021 06:45AM FDA Approves Expanded Indication for Merck’s KEYTRUDA® (pembrolizumab) in Locally Advanced Cutaneous Squamous Cell Carcinoma (cSCC)
Jul 1, 2021 04:06PM Merck (MRK) Provides Update on KEYTRUDA Indication in Third-Line Gastric Cancer in the US
Jul 1, 2021 04:05PM Merck Provides Update on KEYTRUDA® (pembrolizumab) Indication in Third-Line Gastric Cancer in the US
Jun 30, 2021 04:00PM Merck to Hold Second-Quarter 2021 Sales and Earnings Conference Call on July 29
Jun 29, 2021 09:05AM Merck Animal Health Survey Reveals Pet Owners Need Advice Navigating Their Pets' Transition to Normalcy
Jun 29, 2021 06:46AM Merck (MRK) Announces European Commission Approves KEYTRUDA Plus Chemotherapy for Certain Patients With Esophageal Cancer or HER2-Negative Gastroesophageal Junction Adenocarcinoma
Jun 29, 2021 06:45AM European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy for Certain Patients With Esophageal Cancer or HER2-Negative Gastroesophageal Junction (GEJ) Adenocarcinoma
Jun 24, 2021 11:00AM Merck (MRK) Appoints Michael Klobuchar Chief Strategy Officer
Jun 24, 2021 11:00AM Merck Appoints Michael Klobuchar Chief Strategy Officer
Jun 24, 2021 06:47AM Merck's (MRK) LYNPARZA Approved in China for Treatment of Certain Patients with BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
Jun 24, 2021 06:45AM LYNPARZA® (olaparib) Approved in China for the Treatment of Certain Patients with BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
Jun 22, 2021 06:47AM Merck (MRK) Announces Phase 3 KEYNOTE-826 Trial Met Dual Primary Endpoints of OS and PFS in Patients With Persistent, Recurrent or Metastatic Cervical Cancer
Jun 22, 2021 06:45AM Merck Announces Phase 3 KEYNOTE-826 Trial Met Dual Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Patients With Persistent, Recurrent or Metastatic Cervical Cancer
Jun 17, 2021 10:38AM MSD Announces Supply Agreement with U.S. Government for Molnupiravir, an Investigational Oral Antiviral Candidate for Treatment of Mild to Moderate COVID-19
Jun 17, 2021 06:45AM Merck to Participate in the Guggenheim Biopharma Strategy Series
Jun 16, 2021 08:00AM Merck Announces the Kenneth C. Frazier Award for Maternal Health Equity to Accelerate Progress towards Improved Birth Outcomes for All
Jun 15, 2021 07:00AM AtriCure Names Two New Members to the Board of Directors
Jun 9, 2021 06:46AM Merck (MRK) Announces Supply Agreement with U.S. Government for Molnupiravir, an Investigational Oral Antiviral Candidate for Treatment of Mild to Moderate COVID-19
Jun 9, 2021 06:45AM Merck Announces Supply Agreement with U.S. Government for Molnupiravir, an Investigational Oral Antiviral Candidate for Treatment of Mild to Moderate COVID-19
Jun 7, 2021 04:30PM Merck's (MRK) MSD Animal Health to Acquire Assets of LIC Automation Ltd.
Jun 7, 2021 04:30PM MSD Animal Health to Acquire Assets of LIC Automation Ltd.
Jun 7, 2021 06:48AM Merck (MRK) Reports New Data on KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) Versus Sunitinib from Pivotal Phase 3 CLEAR/KEYNOTE-581 Trial
Jun 7, 2021 06:45AM New Data on KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus Sunitinib in First-Line Treatment for Patients With Advanced Renal Cell Carcinoma From Pivotal Phase 3 CLEAR/KEYNOTE-581 Trial
Jun 3, 2021 05:02PM Merck (MRK) KEYTRUDA Reduced the Risk of Disease Recurrence or Death by 32% in RCC
Jun 3, 2021 05:00PM LYNPARZA® (olaparib) Reduced the Risk of Invasive Disease Recurrence or Death by 42% Versus Placebo in Adjuvant Treatment of Patients With Germline BRCA Mutations and High-Risk HER2-Negative Early Br
Jun 3, 2021 05:00PM Merck’s KEYTRUDA® (pembrolizumab) Given After Surgery Reduced the Risk of Disease Recurrence or Death by 32% Versus Placebo as Adjuvant Therapy in Patients With Renal Cell Carcinoma (RCC)
Jun 3, 2021 06:48AM Merck (MRK) Announces Completion of Organon & Co. (OGN) Spinoff
Jun 3, 2021 06:45AM Merck Announces Completion of Organon & Co. Spinoff
Jun 1, 2021 06:48AM Sanofi (SNY) and Merck's (MRK) first and only six-in-one pediatric combination vaccine now available in the United States
Jun 1, 2021 06:45AM Merck and Sanofi’s First and Only Six-in-One Pediatric Combination Vaccine Now Available in the United States
Jun 1, 2021 06:45AM Sanofi and Merck's first and only six-in-one pediatric combination vaccine now available in the United States
May 26, 2021 08:00AM MilliporeSigma Accelerates Scale Up of Lipids to Meet Covid-19 Demand
May 25, 2021 02:04PM Merck Announces Third-Quarter 2021 Dividend
May 24, 2021 06:46AM Merck (MRK) Granted Positive EU CHMP Opinion for KEYTRUDA (pembrolizumab) in Combination with Chemotherapy
May 24, 2021 06:45AM Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as First-Line Treatment for Certain Patients With Esophageal Cancer or HER2-Negative Gastroesoph
May 20, 2021 06:47AM Merck (MRK) Announces Positive Topline Results from PNEU-DIRECTION (V114-027) and PNEU-PLAN (V114-024) Phase 3 Pediatric Studies for V114, Merck’s Investigational 15-valent Pneumococcal Conjugate Va
May 20, 2021 06:45AM Merck Announces Positive Topline Results from PNEU-DIRECTION (V114-027) and PNEU-PLAN (V114-024) Phase 3 Pediatric Studies for V114, Merck’s Investigational 15-valent Pneumococcal Conjugate Vaccine
May 17, 2021 07:00AM Gabrielle Union-Wade Joins 'Don't Skip' Campaign to Encourage Doctor Well-Visits and Recommended Vaccinations
May 13, 2021 06:46AM Merck (MRK) Announces Phase 3 KEYNOTE-522 Trial Met Dual Primary Endpoint of Event-Free Survival in Patients With High-Risk Early-Stage TNBC
May 13, 2021 06:45AM Merck Announces Phase 3 KEYNOTE-522 Trial Met Dual Primary Endpoint of Event-Free Survival (EFS) in Patients With High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
May 12, 2021 07:05AM IMV Inc. Announces First Quarter 2021 Financial and Operational Results and Expansion of its Clinical Pipeline
May 7, 2021 01:05PM Merck (MRK) Declares Record Date and Dividend for the Organon & Co. Spinoff
May 7, 2021 01:01PM Merck Declares Record Date and Dividend for the Organon & Co. Spinoff
May 6, 2021 06:59AM Merck (MRK), Eisai Receive Priority Review From FDA for KEYTRUDA Plus LENVIMA Applications for Advanced Renal Cell Carcinoma and for Advanced Endometrial Carcinoma
May 6, 2021 06:45AM Merck Highlights Scientific Data at 2021 ASCO Annual Meeting Across More Than 20 Cancer Types From Broad Oncology Research Program
May 6, 2021 06:30AM Merck and Eisai Receive Priority Review From FDA for KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Applications for Advanced Renal Cell Carcinoma and for Advanced Endometrial Carcinoma
May 5, 2021 05:26PM Merck (MRK) Announces FDA Approves KEYTRUDA Combined With Trastuzumab and Chemotherapy as First-line Treatment in Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal
May 5, 2021 04:05PM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Combined With Trastuzumab and Chemotherapy as First-line Treatment in Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesoph
View More Recent Stories View Older Stories